An observational study in Acute Cardiovascular Disease, ST-segment Elevation Myocardial Infarction (STEMI) and NSTEMI - Non-ST Segment Elevation MI, sponsored by University Hospital, Basel, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-15.
Sponsored by University Hospital, Basel, Switzerland · Observational
Among 26 studies in ST Elevation Myocardial Infarction with a site in Switzerland — 5 open to participants now, 7 under way, 1 of them phase 3. ST Elevation Myocardial Infarction · Switzerland.
Among the 26 studies in ST Elevation Myocardial Infarction with a site in Switzerland, this one is one of 2 that started in 2024, is one of 5 observational ones, and was the 24th registered.
850 studies on the registry are indexed under ST Elevation Myocardial Infarction; 197 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →5 of the 26 studies in ST Elevation Myocardial Infarction with a site in Switzerland are open now. Recruiting first, the newest first:
École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital Care · Sites in Switzerland
Ages 18+ · Healthy volunteers
IGLESIAS Juan Fernando · Sites in Switzerland
Ages 18+
Novartis Pharmaceuticals · Sites in Switzerland, Argentina, Australia and 11 more countries
Ages 18+
Luzerner Kantonsspital · Sites in Switzerland
Ages 18+
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 122 ST Elevation Myocardial Infarction studies recruiting now, 76 (62%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 3 · Phase 4 3
First in 2007; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200,000 is above the median of 335 across 297 observational studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 300 across the 21 interventional studies, 1,500 across the 5 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 26 have an industry lead sponsor. The 10 most frequent:
University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.
University Hospital, Basel, Switzerland has 1 study filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
5 of the studies in ST Elevation Myocardial Infarction with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-02-11 |
| NCT07810686École Supérieure de Soins Ambulanciers - College of Higher Education in Prehospital CareSmartphone AI Assistance for Prehospital ECG Interpretation | 2026-11-30 |
| NCT04988672Luzerner KantonsspitalOPTIMISER Registry - A Prospective Cohort Study to Describe the OPTIMal Management and Outcomes of PatIents PreSEnting With Acute MyocaRdial Infarction | 2026-12-31 |
| NCT06927791University Hospital, Basel, SwitzerlandMAchine Learning to Boost the Early Diagnosis of Acute Cardiovascular Conditions | 2027-03 |
| NCT05785897IGLESIAS Juan FernandoSTEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT | 2027-03-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 26 studies in ST Elevation Myocardial Infarction with a site in Switzerland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The research project aims to develop clinical decision support tools integrating established diagnostic variables and machine learning (ML) models for rapid diagnosis of acute life-threatening cardiovascular conditions in emergency department (ED) patients with chest pain or dyspnea with the ultimate goal of Improved diagnostic accuracy, faster patient management, and reduced medical errors.
Current State of Research in the Field
Acute cardiovascular disease (ACVD) is the leading cause of death in Switzerland and Europe, responsible for 29% of deaths in Switzerland and 36% across Europe. The increasing prevalence of ACVD, including acute myocardial infarction (AMI), acute heart failure (AHF), pulmonary embolism (PE), and acute aortic syndromes (AAS), places a significant burden on healthcare systems. Diagnosing these conditions in emergency departments (EDs) is challenging due to overlapping symptoms and the need for rapid, accurate decision-making.
The introduction of cardiovascular biomarkers, including high-sensitivity cardiac troponin, B-type natriuretic peptide, and D-dimer has revolutionized early diagnosis. These biomarkers, alongside clinical assessments and electrocardiograms (ECGs), are now essential diagnostic tools. However, current diagnostic algorithms have still tremendous limitations.
Recent advances in machine learning (ML) and deep learning (DL) offer opportunities to improve diagnosis. ML-based ECG interpretation and deep transferable learning (DTL) techniques could enhance diagnostic accuracy by integrating complex ECG and biomarker data. AutoML approaches can further refine these models, reducing human error and improving clinical workflows.
The research team has conducted multiple large-scale studies leading to significant advancements in cardiovascular biomarker research and precision medicine. Their contributions include:
The team is now focussing on integrating ECG data with biomarkers using AI/ML to enhance accuracy and automate decision-making. Collaboration with international experts has enabled the successful application of neural networks to ECG interpretation. The next steps include:
This research aims to revolutionise cardiovascular diagnostics by leveraging AI and ML for more precise, faster, and clinically relevant decision-making.
Objectives:
Dataset of about 200'000 extensively characterized patients enrolled in randomized controlled trials and observational studies are used
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Patients with acute chest pain and/or acute dyspnoea
Other: Machine learning based development of a diagnostic tool for acute cardiovascular disease
MALBEC will be delivered through five integrated work packages (WP) encompassing: (0) platform development and implementation, (1) data pooling, (2) model development, (3) performance comparison, (4) performance validation, and (5) platform plugin
Developing a clinical decision support tool
Developing and implementing a clinical decision support tool that integrates and visualizes results of established diagnostic variables in a dashboard
Time frame: During whole study duration of 3 years
Validate machine learning (ML) models
Derive and validate ML models that integrate cardiac biomarkers with key clinical information and the digital 12-lead ECG to rapidly inform the diagnostic probability for six acute life-threatening cardiovascular conditions in patients presenting with acute chest pain and/or acute dyspnoea to the Emergency Department
Time frame: During whole study duration of 3 years
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Mar 2027, 35 months after the start.
Of 122 non-industry observational studies under ST Elevation Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 107. This study's planned 35 months is below that.
Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 20 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →
University Hospital, Basel, Switzerland →